v3.20.4
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Dec. 31, 2020
Jun. 30, 2020
Current assets:    
Cash and cash equivalents $ 165,526 $ 146,625
Short-term available-for-sale investments 117,426 124,268
Accounts receivable, net of $1,526 and $775 of reserves, respectively 128,243 122,534
Inventories 106,590 103,152
Other current assets 24,148 24,341
Total current assets 541,933 520,920
Property and equipment, net 195,602 176,829
Right of use asset 68,154 71,465
Goodwill 746,666 728,308
Intangible assets, net 504,172 516,545
Other assets 11,339 13,522
Total assets 2,067,866 2,027,589
Current liabilities:    
Trade accounts payable 24,252 23,090
Salaries, wages and related accruals 31,907 31,087
Accrued expenses 13,973 9,093
Contract liabilities 13,217 13,049
Income taxes payable 3,658 2,376
Operating lease liabilities - current 9,912 9,535
Contingent consideration payable 4,983 5,938
Current portion of long-term debt obligations 12,500 12,500
Other current liabilities 3,166 0
Total current liabilities 117,568 106,668
Deferred income taxes 105,342 101,090
Long-term debt obligations 219,035 344,243
Long-term contingent consideration payable 5,599 199
Operating lease liabilities 63,672 67,248
Other long-term liabilities 25,796 26,949
Bio-Techne's shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 38,765,300 and 38,453,046, respectively 388 385
Additional paid-in capital 481,004 420,536
Retained earnings 1,104,762 1,057,470
Accumulated other comprehensive loss (64,238) (97,199)
Total Bio-Techne shareholders' equity 1,521,916 1,381,192
Noncontrolling interest 8,938 0
Total shareholders’ equity 1,530,854 1,381,192
Total liabilities and shareholders’ equity $ 2,067,866 $ 2,027,589

Source